Cognetivity Neurosciences (CGN.C) announced today that its Integrated Cognitive Assessment (ICA) will become an integral part of a new and highly innovative clinic in the UK’s Nation Health Service…
Alzheimer’s
Cognetivity Neurosciences (CGN.C) today announced the publication of the latest scientific paper on its Integrated Cognitive Assessment (ICA) in the peer-reviewed academic journal, Frontiers in Psychiatry. “Empowered by AI,…
Cognetivity Neurosciences (CGN.C) announced today that it has launched in Dubai, United Arab Emirates (UAE), marking the Company’s first expansion into the Middle East. “We’re enormously excited about this…
Core One Labs (COOL.C) announced their wholly-owned subsidiary, Akome Biotech, has begun the development of its patent-pending psychedelic drug formulation for the treatment of Alzheimer’s Disease. Akome’s “next-generation” psychedelic…
Core One Labs (COOL.C) inked a letter of intent to pick up pharmaceuticals company, Akome Biotech today, according to a press release. Akome develops psychedelic-based drugs to treat rare…
The scientific process isn’t exactly what you were taught in grade 4. There’s a lot more to it, owing to some historical—well, let’s call them what they are—atrocities, which…
Cognetivity Neurosciences’ (CGN.C) latest scientific publication touts their Integrated Cognitive Assessment (ICA) tool as a weapon for detecting and monitoring cognitive impairment associated with neurodegenerative diseases. The ICA’s original…
When markets closed Friday November 15, Karuna Therapeutics (KRTX.Q) was just another pharma-stock trading in the mid-teens trying to make drugs for patients with Alzheimer’s and Schizophrenia. Neurodegenerative diseases,…